30 µg/strain of Quadrivalent VLP Vaccine

BIOLOGICAL2 trials

Sponsors

Medicago

Conditions

RNA Virus InfectionsRespiratory Tract DiseasesRespiratory Tract InfectionsVirus Diseases

Phase 2

Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults

CompletedNCT02768805

MedicagoRespiratory Tract Diseases, Respiratory Tract Infections, RNA Virus Infections +1

Start: 2016-03-02End: 2016-11-26Updated: 2020-06-11

Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults

CompletedNCT02831751

MedicagoRespiratory Tract Diseases, Respiratory Tract Infections, RNA Virus Infections +1

Start: 2016-04-30End: 2017-01-31Updated: 2019-10-25